Transthyretin Amyloid Cardiomyopathy Clinical Trial
Global Prevalence of ATTR-CM in Participants With HFpEF
Summary
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with heart failure with preserved ejection fraction (HFpEF)].
Eligibility Criteria
Inclusion Criteria:
Medical history of heart failure (HF) with:
At least 1 episode with clinical evidence of HF (without hospitalization) by signs or symptoms of volume overload or elevated intracardiac pressures that required/requires treatment with a diuretic for improvement; OR
1 prior hospitalization for HF.
Left ventricular ejection fraction (LVEF) >40%.
End-diastolic interventricular septal wall thickness (IVST) ≥12 mm.
Willing and able to undergo scintigraphy.
Exclusion Criteria:
Diagnosis of heart failure with reduced ejection fraction (HFrEF) (EF ≤40%).
Prior clinical history of myocardial infarction, CABG or multi-vessel obstructive coronary disease (>50% stenosis of ≥2 epicardial coronary arteries).
Presence or history of any severe valvular heart disease (obstructive or regurgitant).
A confirmed diagnosis of a non-amyloid infiltrative cardiomyopathy (ie, cardiac sarcoidosis, hemochromatosis), muscular dystrophies, cardiomyopathy with reversible causes, hypertrophic obstructive cardiomyopathy with known genetic etiology, or known pericardial constriction.
Any type of diagnosed amyloidosis (eg, amyloid A amyloidosis, primary [light chain] amyloidosis) or prior diagnosis of ATTR-CM.
-
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 47 Locations for this study
Fairhope Alabama, 36532, United States
Huntsville Alabama, 35801, United States
Miami Florida, 33135, United States
Miami Florida, 33155, United States
Miami Florida, 33165, United States
Miami Florida, 33165, United States
Miami Florida, 33165, United States
Miami Florida, 33175, United States
Ocala Florida, 34471, United States
Hazel Crest Illinois, 60429, United States
Oak Lawn Illinois, 60453, United States
Topeka Kansas, 66604, United States
Topeka Kansas, 66606, United States
New Orleans Louisiana, 70121, United States
Grand Rapids Michigan, 49503, United States
Grand Rapids Michigan, 49525, United States
Tupelo Mississippi, 38801, United States
Tupelo Mississippi, 38801, United States
New York New York, 10016, United States
Raleigh North Carolina, 27610, United States
Jackson Tennessee, 38301, United States
Spokane Washington, 99204, United States
Ottawa Ontario, K1Y 4, Canada
Saint-Jean-sur-Richelieu Quebec, J3A 1, Canada
Trois-Rivieres Quebec, G9A 4, Canada
Bron Cedex , 69677, France
LYON cedex 07 , 69365, France
Nimes , 30029, France
Toulouse cedex 9 , 50032, France
Villeurbanne , 69100, France
Bologna BO, 40138, Italy
Genova Genoa, 16132, Italy
Genova , 16132, Italy
Pavia , 27100, Italy
Pisa , 56124, Italy
Kasugai Aichi, 487-0, Japan
Kasuga Fukuoka, 816-0, Japan
Shinjuku-ku Tokyo, 160-8, Japan
Okayama , 700-8, Japan
Wroclaw Dolnoslaskie, 50-55, Poland
Wrocław Dolnośląskie, 50-55, Poland
Krakow Malopolskie, 31-20, Poland
Białystok Podlaskie, 15-27, Poland
Łódź Łódzkie, 90-54, Poland
Majadahonda Madrid, 28222, Spain
Barcelona , 08035, Spain
Barcelona , 08036, Spain
Barcelona , 08907, Spain
Madrid , 28034, Spain
Salamanca , 37007, Spain
Valencia , 46026, Spain
London , SW17 , United Kingdom
How clear is this clinincal trial information?